Biotheus Inc., a biopharmaceutical company based in China, has announced that its German partner BioNTech (NASDAQ: BNTX) has exercised a global exclusive option right, securing the rights to globally develop, manufacture, and commercialize Biotheus’s in-house developed pre-clinical bispecific antibody (BsAb) candidate drug. Upon the option exercise, Biotheus will receive option fees and an additional payment following the drug’s listing.
This option stems from a license and cooperation agreement established in July 2023, which granted BioNTech the rights to develop, manufacture, and commercialize a pre-clinical BsAb and a clinical BsAb targeting malignant tumors for all markets excluding Greater China.- Flcube.com
